New drug aimed at tough breast cancer enters final testing phase
NCT ID NCT06519370
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests a new drug called FDA018-ADC against standard chemotherapy in 350 people with advanced triple-negative breast cancer that has worsened after taxane treatment. The study compares how long the cancer stays under control and overall survival. Participants are randomly assigned to receive either the new drug or one of several standard chemotherapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FDA018-ADC (an antibody-drug conjugate)
What this could lead to
If it works, this could offer a new treatment option for people with advanced triple-negative breast cancer who have stopped responding to taxane chemotherapy.
What could go wrong
This is a late-stage trial, but the drug may still fail to improve survival or cause serious side effects. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200000, China